Clinical trial · Observational
Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts
NCT02042456CI-TRIAL-00019533terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Change in study staff at the site, change in Sponsor direction
Summary
Brief summary (as posted)
This study is investigating whether automated whole breast ultrasound can improve detection of cancer in breast cancer screening when used as a supplement to mammography or as a supplement to digital breast tomosynthesis
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Automated Whole Breast Ultrasound | Device | — | UNRESOLVED |
| Digital Breast Tomosynthesis | Device | — | UNRESOLVED |
| Full Field Digital Mammography | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Main Cohort
- description
- Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
- interventionNames
- Device: Digital Breast Tomosynthesis
- Device: Automated Whole Breast Ultrasound
- Device: Full Field Digital Mammography
Primary outcomes (1)
- measure
- Abnormal interpretation rate
- timeFrame
- One Year
- description
- Abnormal interpretation rates for each modality (FFDM and DBT+V-Preview, with and without ABUS+V-Preview).
Secondary outcomes (5)
- measure
- Sensitivity
- timeFrame
- One Year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able and willing to provide signed declaration of informed consent or have a legally authorized representative provide signed declaration of informed consent for participation in all study procedures; * Women aged ≥18 years at the time of enrollment;\* * Women with a previous determination of dense breasts determined by mammogram as heterogeneously dense or extremely dense; * At moderately increased or high risk (\>15% lifetime risk) for breast cancer based on meeting one or more of the ACS criteria 1: AND Referred for screening mammography Exclusion Criteria: * Have been screened using any breast imaging technology in \<12 months immediately prior to enrollment; * Exhibit breast cancer symptoms according to assessment by the subject's health care provider within one year prior to enrollment; * Diagnosed with breast cancer, with or without metastasis, within one year prior to enrollment; * Are currently pregnant as determined per standard clinical practice at the investigational site; * Present with contraindications to any imaging examination required in the study protocol; * Have breast implants; OR * Are lactating.
References
Publications (0)
Data not yet available
No reference posted for this study.